Trial intelligence / Profile preview

MBP8298 (dirucotide) in HLA-DR2/DR4-positive secondary progressive multiple sclerosis

2004-002571-16Phase 2Completed

Sponsor: BioMS Medical Corp.
Start: Feb 2005
Modality: Peptides
Countries: 1

Overview

Phase 2, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing MBP8298 (dirucotide) with Placebo (2 arms). Primary endpoint: Time to confirmed disability worsening. Started Feb 2005; status: completed.

Drugs

dirucotide

Conditions

secondary-progressive multiple sclerosis (SPMS)

Beyond the preview

Go deeper on 2004-002571-16.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-002571-16.